Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2009

OctoPlus Signs Contract with Axentis for Inhaled CF Therapy

  • OctoPlus signed a development and manufacturing contract with Axentis Pharma. Under terms of the deal, OctoPlus will carry out process development and clinical manufacturing of Axentis’ lead product, an inhaled liposomal formulation of tobramycin. The product, Fluidosomes™-tobramycin (also known as ARB-CF0223), is in development for the treatment of respiratory infections in cystic fibrosis patients.

    Axentis started a Phase II trial with Fluidosomes™-tobramycin in September 2008. In April 2009 the product received orphan drug designation in the U.S. for the treatment of pulmonary infections caused by Pseudomonas aeruginosa. In July FDA granted the product a second orphan drug designation or the treatment of pulmonary infections caused by Burkholderia cepacia pathogens.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »